EDMONTON, Alberta, June 18, 2015 – BioNeutra Global Corporation (CSE: BGA) (“BioNeutra” or the “Company“) is pleased to announce that it has engaged CHF Investor Relations (“CHF”), a highly regarded Canadian investor relations firm headquartered in Toronto, as its IR partner.
Mr. Bill Smith, Chairman & Senior Vice President of BioNeutra Global Corporation, commented, “We are excited to retain CHF, as they have superior knowledge of the nutraceutical and food industry, as well as many decades of capital markets experience. This will be a true value-added partnership for BioNeutra.”
Effective immediately, the services agreement for investor relations and market-making is for a term of twelve months to June 14, 2016, subject to three months termination notice and may be extended for up to one year. Under the terms of the agreement, which is subject to Canadian Stock Exchange approval, CHF will receive $6,000 per month in fees and reimbursement of expenses. CHF will be granted 225,000 options exercisable at $0.55 and 225,000 options exercisable at $0.75. The options vest quarterly over twelve months and have a five-year term. Upon termination of the services agreement, any vested options will be cancelled after 30 days, as required by the CSE.
The market-making activity will be conducted using a registered broker in compliance with IIROC’s Universal Market Integrity Rules & Policies (2010) and other relevant policies, so that trading orders in BioNeutra’s shares are made to manage share price volatility and imbalances of orders to improve trading liquidity on the exchange. The Company and CHF confirm that capital for the purposes of market-making has not and will not be provided from the Company’s treasury. Prior to the grant of options outlined above, CHF had no direct or indirect interest in the Company or its securities.
About CHF Investor Relations
CHF’s effective role is to act as the public company’s outsourced, low-cost equivalent to an internal investor relations department. CHF serves an international portfolio of TSX/TSX Venture and CSE listed companies, and others that may seek to list on North American Exchanges that operate in a broad range of industries including mining exploration and producers, oil & gas, renewable energy and industrial services, biotech, high-tech, business solutions and products. The depth of capital market experience at CHF is formidable dating back to the late 1970s.
About BioNeutra Global Corporation
BioNeutra is in the business of research and development, production and commercialization of ingredients for nutraceutical, functional and mainstream foods and beverages, with a focus on oligosaccharides.
The Company’s lead product, VitaFiber™, is an advanced functional and health food ingredient scientifically made from natural agricultural products, is generally regarded as safe (GRAS) by the U.S. Food & Drug Administration, and is European Food Safety Authority and Health Canada approved. VitaFiber™ is naturally sweet and lower in calories than regular sugar and is a natural source of dietary fiber as it provides low calorie soluble prebiotic fiber for human digestive health.
The Company produces VitaFiber™ using its patented processes that naturally transforms starch molecules from agriculture cereal crops including corn, wheat, barley, potato, or tapioca into the functional health molecules of isomalto-oligosaccharide (IMO). The VitaFiber™ manufacturing process is based upon a natural enzymatic conversion of starch molecules without any chemical modification involved, making VitaFiber™ a natural food ingredient. VitaFiber™ is also non-GMO, vegan-friendly, gluten-free, Kosher and Halal certified and available as certified organic.
The Company’s customers include a mix of small and medium enterprises and a number of high-profile food manufacturers in Canada, the U.S., Europe, the United Kingdom, and Mexico. VitaFiber™ is also available for retail purchase across the globe through Amazon.com and other direct-to-consumer retailers.
Issued on behalf of the Board of Directors of BioNeutra Global Corporation.
BioNeutra Global Corporation
Bill Smith, Chairman & Senior Vice President
T: (780) 466-1481 x 117
CHF Investor Relations
Stephanie Batcules, Account Manager
T: +1 416 868 1079 x225